Introduction {#sec1_1}
============

Alzheimer disease (AD) is the most common type of dementia among older adults. Early deposits of cerebral amyloid-beta and tau protein are distinctive markers of AD, and their histological quantification remains a hallmark for definitive diagnosis \[[@B1]\]. However, cerebral small-vessel disease (SVD) frequently coexists with AD pathology. Recent studies recognize similar vascular risk factors for both SVD and AD \[[@B2]\]. In addition, post-mortem studies demonstrate the presence of vascular lesions in up to 79.9% of individuals with pathologically confirmed AD \[[@B3]\], leading to the recognition that pure forms of dementia in the elderly are relatively infrequent.

SVD is a disease that affects small arteries, arterioles, veins, and capillaries of the brain and is considered the most frequent cause of vascular dementia. Recent standardization of SVD lesions on conventional magnetic resonance imaging (MRI) includes small subcortical infarcts, lacunar strokes, white matter hyperintensities (WMH), dilated perivascular spaces, and brain atrophy, allowing the neuroradiological diagnosis of cerebral SVD \[[@B4]\]. The Fazekas scale (FS) \[[@B5]\] is a widely used method to quantify the severity of WMH lesions on T2/FLAIR sequences.

Other than subcortical lesions, SVD also induces atrophy in cortical regions \[[@B5]\]. Routine clinical use of rating scales allows imaging assessment of cerebral atrophy in dementia. The Scheltens scale (SS) \[[@B6]\] is commonly used to measure brain hippocampal atrophy in coronal T1-weighted images, whereas the Koedam scale (KS) \[[@B7]\] enables the visual assessment of parietal atrophy associated with early-onset AD.

Atrophy and WMH are common neuroradiological findings, but few studies have associated these insults with cognition in community-dwelling populations \[[@B8]\]. The extent of WMH has been associated with cognitive impairment. Similarly, a higher risk of developing dementia has been suggested among mild cognitive impairment (MCI) patients with higher SVD burden \[[@B9]\]. By quantifying WMH and hippocampal and parietal atrophy, we aimed to describe the prevalence and severity of SVD among older adults with normal cognition (NC), MCI, and probable AD and to describe associated risk factors.

Materials and Methods {#sec1_2}
=====================

Participants {#sec2_1}
------------

This cross-sectional study was conducted at the Memory Clinic of a tertiary-level University Hospital in Mexico City. A total of 105 older adults aged 60 years or older were consecutively recruited. Each subject completed clinical and neuropsychological evaluations between June 2015 and June 2016. Based on the results of the evaluations, subjects were allocated to 3 different groups: NC, MCI, or AD. For this study, we excluded subjects with major depression, non-AD dementias, other neurological disorders, including structural cerebral lesions that could affect cognitive functions (i.e., acute stroke, brain tumors, or normal pressure hydrocephalus), as well as subjects without available MRI. The local Ethics Committee approved this study.

Neuropsychological Evaluation {#sec2_2}
-----------------------------

A functional and neuropsychological evaluation was performed in order to establish the subject\'s cognitive status (dependent variable), including the following tests: Mini-Mental State Examination (MMSE) for the evaluation of global cognition (scores between 24 and 30 were included) \[[@B10]\].Clinical Dementia Rating Scale (score = 0.5) for the evaluation of cognitive and functional performance \[[@B11]\].The Katz Index of Independence in Activities of Daily Living (ADL) and the Lawton Instrumental Activities of Daily Living (IADL) Index were used for the assessment of functional status \[[@B12], [@B13]\]. A subject was considered independent for ADL when the score was ≥6 and dependent when the score was \< 6. A subject was considered independent for IADL when the score was = 8 and dependent when the score was ≤7 for women and ≤5 for men.The brief Neuropsychological Evaluation in Spanish (NEUROPSI) \[[@B14]\] was used for the assessment of specific domains affected differentially in cerebral impairment. The cognitive domains evaluated in various subtests of the NEUROPSI include orientation, attention and concentration, language, memory, executive functions, reading, writing, and calculation. - MCI diagnosis was established according to Petersen\'s \[[@B15]\] criteria: (1) memory complaints or increased forgetfulness; (2) memory impairment (according to standardized neuropsychological tests); (3) the cognitive deficits do not interfere with activities of daily living; and (4) absence of dementia diagnosis.- Dementia diagnosis was established in a 2-step approach: first, a neurologist performed a clinical and neurological evaluation, and second, a neuropsychological evaluation was conducted by an expert neuropsychologist. Diagnostic agreement was established according to DSM-IV criteria \[[@B16]\]. Probable AD diagnosis was based on previously published international criteria \[[@B17]\].- NC was considered if subjects denied a memory complaint and performed normally in the battery of neuropsychological tests according to age and educational level \[[@B18]\].

Sociodemographic and Clinical Variables {#sec2_3}
---------------------------------------

Information about subjects\' age, sex, educational level (in years), body mass index (in kg/m^2^), history of smoking, alcoholism, presence or absence of traumatic cerebral lesions, and chronic diseases, such as diabetes, hypertension, hypothyroidism, cardiovascular disease, atrial fibrillation, and vascular cerebral diseases was recorded. Depressive symptoms were evaluated with the 15-item version of the Geriatric Depression Scale (GDS-15); a score \> 5 was considered positive for depressive symptoms \[[@B19]\].

Brain MRI Studies {#sec2_4}
-----------------

All subjects underwent an MRI using a standard protocol. Images were obtained with a 1.5-T Magnetic Resonance Scanner (Siemens® Medical Systems), including whole-brain T2-weighted, T1-weighted, and T2\*-weighted gradient-recalled echo, FLAIR, and diffusion sequences. A neuroradiologist performed the MRI assessments blinded to the subjects\' clinical information.

Visual Classification {#sec2_5}
---------------------

WMH were evaluated on axial T2-weighted and FLAIR sequences using the FS \[[@B5]\] and classified according to the following stages: 0 (absence of lesions), 1 (nonconfluent lesions), 2 (confluent lesions), and 3 (diffuse lesions). The degree of medial temporal atrophy was rated on T1-weighted images according to the SS \[[@B6]\] as follows: 0 (no atrophy), 1 (mild atrophy), 2 (mild/moderate atrophy), 3 (moderate/marked atrophy), and 4 (marked atrophy). Parietal atrophy was assessed on T1-weighted images with the use of the KS \[[@B7]\] consisting of 4 stages: 0 (no atrophy), 1 (mild atrophy), 2 (moderate atrophy), and 3 (severe atrophy). Cerebral microbleeds were evaluated on T2\*-weighted gradient sequences with a dichotomized classification according to presence or absence.

Statistical Analysis {#sec2_6}
--------------------

Variables were described using arithmetic means, standard deviations, frequencies, and proportions. Categorical variables were compared using the χ^2^ test. Analysis of variance (ANOVA) and post hoc Bonferroni analysis were used to identify differences between groups. Multivariate logistic regression models were constructed in order to identify the association between the severity in the FS, KS, and SS scoring results and the presence of cognitive impairment, adjusting for age, educational level, and cardiovascular risk factors (diabetes, hypertension, dyslipidemia, and current smoking status). Associations were considered significant at the 0.05 level. Analyses were performed using SPSS version 22 for Windows® (Chicago, IL, USA).

Ethical Issues {#sec2_7}
--------------

The research protocol was reviewed and approved by the Institutional Review Board at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran. All study participants signed an informed consent.

Results {#sec1_3}
=======

The mean age of subjects was 75.3 ± 7.9 years, 68% were women, and the mean educational level was 8.9 ± 6.5 years. Thirty subjects (28%) had a probable AD diagnosis, 41 (39%) had MCI, and 34 (32%) had NC. As seen in Table [1](#T1){ref-type="table"}, compared to the NC and MCI groups, patients in the probable AD group were older (*p* \< 0.05), had a lower level of education (*p* \< 0.05) and a higher frequency of dyslipidemia (76%, *p* \< 0.05), and were smokers (76%, *p* \< 0.05). As for cognitive performance, the most severely affected group in all the cognitive domains assessed by the MMSE and the NEUROPSI was the AD group (*p* \< 0.001).

Table [2](#T2){ref-type="table"} presents the imaging characteristics of cerebral SVD on MRI findings. According to the FS, 8.8, 17.3, and 73% of NC, MCI, and probable AD subjects, respectively, were in stage 2 (*p* \< 0.001). According to the SS, 0, 2.4, and 33.3% of NC, MCI, and probable AD subjects, respectively, were in stage 3 (*p* \< 0.001), and according to the KS, 2.9, 14.6, and 23.3% of NC, MCI, and probable AD subjects, respectively, were in stage 2 (*p* \< 0.001). Lobar cerebral microbleeds were present in 20% of probable AD subjects, in 2.4% of MCI subjects, and in 0% of NC subjects (*p* = 0.002).

As seen in Table [3](#T3){ref-type="table"}, in the nonadjusted model of the multinomial logistic regression of the FS, SS, and KS scoring results and their association with the presence of MCI and probable AD, we observed an increased risk of probable AD of 16 times (OR = 16, 95% CI 5--47, *p* \< 0.001) and an increase of 2.7-fold in the MCI group (OR = 2.7, 95% CI 1.2--5.8, *p* = 0.010). After adjusting for possible confounding factors, the risk persisted 7.6-fold using the FS in the probable AD group (OR = 7.6, 95% CI 2.7--20, *p* \< 0.001), with a tendency in the MCI group (OR = 2.2, 95% CI 0.90--5.5, *p* = 0.08). When using the SS, the risk remained significant for probable AD (OR = 4.5, 95% CI 3.5--58, *p* = 0.003) but not for MCI (OR = 1.3, 95% CI 0.3--5.5, *p* = 0.69). Finally, when using the KS, the association with probable AD had an OR of 8.9 (95% CI 1--72, *p* = 0.04) and with MCI had an OR of 0.78 (95% CI 12--4.3, *p* = 0.74).

Discussion {#sec1_4}
==========

To our knowledge, there are no studies in Mexican populations that describe the neuroimaging characteristics of SVD. Latin-American countries share high cardiovascular risk profiles, which potentially interact with AD pathology. SVD, which is generally asymptomatic and commonly associated with cardiovascular risk factors, is a prevalent disease in older persons \[[@B20], [@B21]\]. SVD has been found to contribute to up to 45% of dementias \[[@B22]\].

In this study, the presence of SVD was evaluated with the use of the FS. In addition, we quantified hippocampal and parietal brain atrophy with the SS and the KS, respectively, demonstrating atrophy in participants with MCI and AD compared to NC subjects. Temporal atrophy measured with the SS was present in MCI cases and reached the most severe values in probable AD subjects. These findings agree with previous studies \[[@B23], [@B24]\] showing an association between SVD and cortical atrophy regardless of the type of dementia, suggesting that vascular factors could be involved in the pathogenesis of cerebral atrophy in the elderly.

Lobar microbleeds were found in 20% of probable AD subjects and in 2.4% of MCI subjects, in agreement with other studies \[[@B25], [@B26]\]. Recently, an association between microbleeds and cognitive impairment has been suggested, but the mechanisms of this association remain poorly understood \[[@B4]\].

Both MCI and probable AD subjects had a greater prevalence of cardiovascular risk factors compared with NC subjects. Wang et al. \[[@B27]\] have previously demonstrated that the inflammatory, metabolic, and microvascular changes that accompany Western diets, obesity, metabolic syndrome, diabetes, dyslipidemia, and hypertension have important roles in the progression of cognitive impairment, highlighting the strong correlation existing between these factors and the development of SVD.

Our findings support the occurrence of important interactions between MCI, SVD, and AD dementia. Erten-Lyons et al. \[[@B28]\] have demonstrated an association between AD pathology and alterations of cerebral white matter integrity. On the same basis, Provenzano et al. \[[@B29]\] previously suggested that the degree of SVD burden could distinguish between patients with NC and AD, with excellent sensitivity and acceptable specificity.

The nonadjusted models showed an association between SVD severity and decreased cognitive performance, which persisted in probable AD subjects after adjusting for age, educational level, and known cardiovascular risk factors with the FS, SS, and KS. Other studies \[[@B30], [@B31], [@B32]\] have previously demonstrated the association between cerebral white matter lesions and reduced cognitive performance, although some results lacked statistical power \[[@B1]\]. In the present study, the association persisted particularly in probable AD subjects, with a tendency in the MCI group on the FS. Other small studies \[[@B33]\] have also demonstrated low cognitive performance in a small group of elderly patients with SVD.

Our study had some limitations, including its cross-sectional design, which cannot explain the underlying causative mechanisms of cognitive impairment. The calculated convenience sample could affect the study\'s external validity. Intra- and interobserver reproducibility for brain imaging was not calculated. Future longitudinal studies with larger samples should allow us to better determine the association and potential cause-effect link between SVD and cognition, preferably with the support of histopathology and biomarkers in subjects with AD.

The use of visual scales is useful to evaluate and quantify SVD on MRI. Adequate identification and knowledge of these lesions could allow the establishment of possible measures for their prevention. For these reasons, it is necessary that all specialists involved in the care of patients with dementia identify and classify these vascular lesions quantitatively.

Statement of Ethics {#sec1_5}
===================

The research protocol was reviewed and approved by the Institutional Review Board at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran. All study participants signed an informed consent.
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###### 

Sociodemographic characteristics, cardiovascular risk factors, and cognitive performance in NC, MCI, and probable AD subjects

                                                         NC (*n* = 34)                                                                 MCI (*n* = 41)                                                               Probable AD (*n* = 30)                                                        *p*
  ------------------------------------------------------ ----------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------
  Age, years                                             70±6.8[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"},   75±5.8[^B^](#T1F2){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}   80±8.3[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}    \<0.001
  Female                                                 24 (70)                                                                       22 (53)[^B^](#T1F2){ref-type="table-fn"}                                     23 (76)[^B^](#T1F2){ref-type="table-fn"}                                      0.100
  Education, years                                       12±5[^A^](#T1F1){ref-type="table-fn"}                                         10±7.3[^B^](#T1F2){ref-type="table-fn"}                                      3±3.8[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}     \<0.001
  Body mass index                                        26±3.8[^A^](#T1F1){ref-type="table-fn"}                                       25±3.7[^B^](#T1F2){ref-type="table-fn"}                                      23±4.2[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}    0.072
                                                                                                                                                                                                                                                                                                  
  Type 2 diabetes                                        3 (8)[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}     18 (43)[^C^](#T1F3){ref-type="table-fn"},                                    10 (33)[^A^](#T1F1){ref-type="table-fn"}                                      0.002
  Hypertension                                           13 (38)[^C^](#T1F3){ref-type="table-fn"},                                     25 (61)[^C^](#T1F3){ref-type="table-fn"},                                    16 (53)                                                                       0.045
  Dyslipidemia                                           13 (38)[^A^](#T1F1){ref-type="table-fn"}                                      14 (35)[^B^](#T1F2){ref-type="table-fn"}                                     23 (76)[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}   \<0.001
  Smoking status, yes                                    12 (35)[^A^](#T1F1){ref-type="table-fn"}                                      20 (48)[^B^](#T1F2){ref-type="table-fn"}                                     23 (76)[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}   \<0.001
                                                                                                                                                                                                                                                                                                  
  GDS                                                    2±2.2[^A^](#T1F1){ref-type="table-fn"}                                        3±2.7                                                                        3±2.9[^A^](#T1F1){ref-type="table-fn"}                                        0.035
  Katz                                                   5±0.3[^A^](#T1F1){ref-type="table-fn"}                                        5±0.41[^B^](#T1F2){ref-type="table-fn"}                                      4±1.5[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}     \<0.001
  Lawton                                                 7±0.3[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}     6±1.4[^B^](#T1F2){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}    2±2.0[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}     \<0.001
  MMSE                                                   29±0.91[^A^](#T1F1){ref-type="table-fn"}                                      27±4.2[^B^](#T1F2){ref-type="table-fn"}                                      14±5.6[^A^](#T1F1){ref-type="table-fn"}, [^B^](#T1F2){ref-type="table-fn"}    \<0.001
                                                                                                                                                                                                                                                                                                  
  NEUROPSI                                                                                                                                                                                                                                                                                        
   Orientation                                           6±0[^A^](#T1F1){ref-type="table-fn"}                                          6±0[^B^](#T1F2){ref-type="table-fn"}                                         4.57±1                                                                        \<0.001
   Attention                                             20.7±3[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}    16.5±4[^B^](#T1F2){ref-type="table-fn"}                                      12.5±4                                                                        \<0.001
   Memory                                                40.6±4[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}    34.1±7[^B^](#T1F2){ref-type="table-fn"}                                      20.3±3                                                                        \<0.001
   Language                                              23.2±3[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}    21.4±2[^B^](#T1F2){ref-type="table-fn"}                                      18.5±2                                                                        \<0.001
   Reading and writing                                   4.8±0.5[^A^](#T1F1){ref-type="table-fn"}                                      4.7±2.5[^B^](#T1F2){ref-type="table-fn"}                                     2±2                                                                           \<0.001
   Executive functions                                   15.8±2[^A^](#T1F1){ref-type="table-fn"}, [^C^](#T1F3){ref-type="table-fn"}    13.5±3[^B^](#T1F2){ref-type="table-fn"}                                      8.7±4                                                                         \<0.001
   Visuospatial and visuoconstructive (copy) abilities   12.2±8                                                                        10.6±2                                                                       7.8±3                                                                         0.052

Values are means ± standard deviations or *n* (%). NC, normal cognition; MCI, mild cognitive impairment; AD, Alzheimer disease; GDS, Geriatric Depression Scale; Katz, Index of Independence in Activities of Daily Living; Lawton, Instrumental Activities of Daily Living Index; MMSE, Mini-Mental State Examination; NEUROPSI, brief Neuropsychological Evaluation in Spanish.

Post-hoc Bonferroni analysis: AD versus NC, *p* \< 0.05

Post-hoc Bonferroni analysis: AD versus MCI, *p* \< 0.05

Post-hoc Bonferroni analysis: MCI versus NC, *p* \< 0.05.

###### 

Bivariate analysis to demonstrate the differences between the groups according to SMD quantification by the Fazekas, Scheltens (hippocampal atrophy), and Koedam (parietal atrophy) scales on MRI

                                                                                                                           Classification   NC, *n* (%) (*n* = 34)   MCI, *n* (%) (*n* = 41)   AD, *n* (%) (*n* = 30)   *p*
  ------------------------------------------------------------------------------------------------------------------------ ---------------- ------------------------ ------------------------- ------------------------ ---------
  Fazekas scale[^A^](#T2F1){ref-type="table-fn"}, [^B^](#T2F2){ref-type="table-fn"}, [^C^](#T2F3){ref-type="table-fn"}     0                16 (47.1)                6 (14.6)                  2 (6.7)                  \<0.001
                                                                                                                           1                15 (44.1)                28 (68.3)                 6 (20)                   
                                                                                                                           2                3 (8.8)                  7 (17.3)                  22 (73)                  
                                                                                                                           3                0                        0                         0                        
                                                                                                                                                                                                                        
  Scheltens scale[^A^](#T2F1){ref-type="table-fn"}, [^B^](#T2F2){ref-type="table-fn"}, [^C^](#T2F3){ref-type="table-fn"}   0                21 (61.8)                18 (43.9                  0                        \<0.001
                                                                                                                           1                11 (3.4)                 15 (36.6)                 5 (16.7)                 
                                                                                                                           2                2 (5.9)                  7 (17.1)                  13 (43.4)                
                                                                                                                           3                0                        1 (2.4)                   10 (33.3)                
                                                                                                                           4                0                        0                         2 (6.0)                  
                                                                                                                                                                                                                        
  Koedam scale[^A^](#T2F1){ref-type="table-fn"}, [^B^](#T2F2){ref-type="table-fn"}, [^C^](#T2F3){ref-type="table-fn"}      0                17 (50)                  13 (31.7)                 0                        \<0.001
                                                                                                                           1                16 (47.1)                22 (53.7)                 22 (73.3)                
                                                                                                                           2                1 (2.9)                  6 (14.6)                  7 (23.3)                 
                                                                                                                           3                0                        0                         1 (3.3)                  
                                                                                                                                                                                                                        
  Lobar microbleeds[^A^](#T2F1){ref-type="table-fn"}, [^B^](#T2F2){ref-type="table-fn"}                                    Presence         0                        1 (2.4)                   6 (20)                   0.002
                                                                                                                           Absence          34 (100)                 40 (97.6)                 24 (80)                  

SMD, small-vessel disease; MRI, magnetic resonance imaging; NC, normal cognition; MCI, mild cognitive impairment; AD, Alzheimer disease.

Post-hoc Bonferroni analysis: AD versus NC, *p* \< 0.05

Post-hoc Bonferroni analysis: AD versus MCI, *p* \< 0.05

Post-hoc Bonferroni analysis: MCI versus NC, *p* \< 0.05.

###### 

Unadjusted multinomial regression model and adjustment in patients with MCI and AD (the independent variables analyzed were the Fazekas, Scheltens, and Koedam scales)

  NC (reference category)   Nonadjusted model   Model 1: age and education   Model 2: cardiovascular risk factors                                                  
  ------------------------- ------------------- ---------------------------- -------------------------------------- ------ ----------- --------- ----- ----------- ---------
  Fazekas scale                                                                                                                                                    
   MCI                      2.7                 1.2--5.8                     0.010                                  2.5    1.1--5.7    0.020     2.2   0.90--5.5   0.08
   AD                       16.1                5--47                        \<0.001                                18.0   4.8--66     \<0.001   7.6   2.7--20     \<0.001
                                                                                                                                                                   
  Scheltens scale                                                                                                                                                  
   MCI                      1.9                 1.0--3.9                     0.05                                   1.8    0.90--3.8   0.09      1.3   0.31--5.5   0.69
   AD                       15.5                5.5--43                      \<0.001                                33.0   6.6--67     \<0.001   4.5   3.5--58     0.003
                                                                                                                                                                   
  Koedam scale                                                                                                                                                     
   MCI                      2.5                 1.0--5.7                     0.03                                   3.0    1.1--7.6    0.02      0.7   0.12--4.3   0.74
   AD                       9.0                 3.1--25                      \<0.001                                9.1    6.1--13     \<0.001   8.9   1.0--72     0.04

Model 1: adjustment for age and level of education. Model 2: adjustment for diabetes mellitus, hypertension, dyslipidemia, and smoking status. MCI, mild cognitive impairment; AD, Alzheimer disease; NC, normal cognition; OR, odds ratio; CI, confidence interval.
